Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

Orbis Medicines raises €90M Series A led by NEA for macrocycle drug development, with backing from Eli Lilly, Cormorant Asset ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown ...

Iambic Therapeutics has hired a CFO, poaching an executive who helped engineer the first big merger in the AI-driven biotech ...

Oculis' OCS-05 succeeds in Phase 2 trial for acute optic neuritis, showing improved vision and retinal measures. FDA clears ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million, roughly a week after WuXi AppTec also announced it's shrinking its ...

I-Mab halts CD73 program to focus on givastomig, General Proximity emerges with $16M for undruggable proteins, PBS Biotech raises $17M, Citius explores sale ...

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

Anticipation builds for Eli Lilly's oral obesity drug orforglipron's trial results in 2025, following Novo Nordisk's ...

Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.

Drugmakers are expected to increase list prices on more than 1,000 medicines this year, and already raised the prices on ...